Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8
Interventions: BIOLOGICAL: Pembrolizumab|DRUG: Tamoxifen|DRUG: Vorinostat
Sponsor: University of California, San Francisco
Collaborators: Merck Sharp & Dohme LLC